Trial Profile
A Randomised, Double-Blind, Placebo-Controlled, Single- Dose, Dose-Escalation Trial of Anti-IL-20 in Healthy Volunteers and Patients With Rheumatoid Arthritis.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Interleukin 20 receptor antagonists (Primary)
- Indications Inflammation; Rheumatoid arthritis
- Focus Adverse reactions; Biomarker
- Sponsors Novo Nordisk
- 21 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Oct 2009 Planned end date changed from 1 Sep 2009 to 1 Jan 2010 as reported by ClinicalTrials.gov.
- 29 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.